← Back to patent-cliff list
戊酸雌二醇/醋炔诺酮
Tier C — Watch / tradeEstradiol Valerate/Norethindrone Acetate
卡德博士制药有限公司
Originator
2006
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ERs、PR
Brand：Cliovelle、Cliovellan
Indications (approved)：雌激素缺乏综合征、绝经期后骨质疏松
Regional status
US
-
EU
批准上市
2006-02-03
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Estradiol Valerate/Norethindrone Acetate?
Approved indications include: 雌激素缺乏综合征, 绝经期后骨质疏松.
When does the Estradiol Valerate/Norethindrone Acetate patent expire?
No public expiry year is available for Estradiol Valerate/Norethindrone Acetate yet; this page updates once verified.
How do I get a quote for Estradiol Valerate/Norethindrone Acetate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24